Table 2.
Summary of gene-specific methylation data in VHL-associated and sporadic phaeochromocytomas and neuroblastoma tumours
| Phaeochromocytoma (% methylated) | ||||
|---|---|---|---|---|
| All | VHL | Sporadic | Neuroblastoma tumours (% methylated) | |
| OPCML | 12 (4/33) | 10.5 (2/19) | 14.3 (2/14) | 10.5 (2/19) |
| CTNNG | 3 (1/33) | 0 (0/19) | 7.1 (1/14) | 10.5 (2/19) |
| HOXA9 | 17.2 (5/29) | 25 (4/16) | 7.7 (1/13) | 22.2 (4/18) |
| EMP3 | 6.1 (2/33) | 5.3 (1/19) | 7.1 (1/14) | 68.4 (13/19) |
| SYK | 0 (0/29) | 0 (0/16) | 0 (0/13) | 0 (0/18) |
| HSP47 (A) | 36.4 (12/33) | 36.8 (7/19) | 35.7 (5/14) | 68.4 (13/19) |
| HSP47 (B) | 51.5 (17/33) | 52.6 (10/19) | 50 (7/14) | 89.5 (17/19) |
| TMS1 | 6.9 (2/29) | 0 (0/16) | 15.4 (2/13) | 16.7 (3/18) |
Data are percentages and numbers of tumour samples analysed. Methylation of EMP3 and HSP47 (A) and HSP47 (B) was significantly more frequent in neuroblastomas than phaeochromocytomas (P=0.001, P=0.02 and P=0.005 respectively).